XNAS
AZTA
Market cap1.69bUSD
Oct 08, Last price
36.00USD
1D
0.31%
1Q
41.96%
Jan 2017
110.90%
Name
Azenta Inc
Chart & performance
P/E
—
P/S
2.79
EPS
—
Div yield, %
—
Shrs. gr., 5y
-9.07%
Rev. gr., 5y
8.85%
Revenues
594m
+3.55%
Net income
-56m
L-66.18%
CFO
72m
+45.11%
Dividend
Dec 02, 20210.1 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
Key people
Frank Casal
Independent Chairman of the Board · since 2024
Lawrence Lin
Chief Financial Officer, Executive Vice President · since 2024
Jason Joseph
Senior Vice President, General Counsel, Secretary · since 2017
Olga Pirogova
Chief Human Resources Officer, Senior Vice President · since 2023
Ephraim Starr
Senior Vice President, General Counsel, Corporate Secretary · since 2025
Ginger Zhou
Senior Vice President, General Manager - Multi-Omics · since 2024
John Marotta
President, Chief Executive Officer, Director · since 2024
William Cornog
Independent Director · since 2024
Independent Director · since 2013
Dipal Doshi
Independent Director · since 2025
Quentin Koffey
Independent Director · since 2024
Independent Director · since 2024
Independent Director · since 2020
Tina Nova
Independent Director · since 2023
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
200 SUMMIT DRIVE
BURLINGTON, MA 01803
US
BURLINGTON, MA 01803
US
Previous name
Brooks Automation, Inc.
Previous name
Brooks-Pri Automation, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||